This application requests Cancer Center Support Grant funding for the Holden Comprehensive Cancer Center (HCCC) at the University of Iowa. This is the second CCSG competitive renewal for the HCCC. The HCCC functions administratively as a matrix Cancer Center with 189 Center members from six colleges and 36 departments across the University. It leverages the resources and expertise provided by the medical center and across the University to support and strengthen transdisciplinary cancer research. The HCCC has extensive support from both the institution and via private support. The members of the HCCC have $74.2 million in total annual cancer-related, peer-reviewed, external research support. Of this, over $20.4 million comes from the NCI. The HCCC is organized into six research programs that are each designed to be translational in nature. Together they encompass a broad spectrum of strength in basic laboratory, clinical and population research. These programs are 1) Cancer Immunology &Immunotherapy, 2) Cancer Signaling and Experimental Therapeutics, 3) Free Radical Cancer Biology, 4) Tumor Imaging, 5).Cancer Epidemiology, and 6) Cancer Genomics and Cell Growth. In addition to the Administrative Core, the HCCC supports eleven shared resources including: 1) DNA, 2) Gene Transfer Vector, 3) Radiation and Free Radical Research, 4) Flow Cytometry, 5) Central Microscopy Research Facility, 6) Small Animal Imaging, 7) Tissue Procurement 8) Bioinformatics, 9) Population Research, 10) Biostatistics, and 11) Clinical Trials Support. Through these programs and cores, and an effective organizational structure, the HCCC enhances interactions, supports collaborations, and sets the direction of future cancer research activities at the HCCC.
The Cancer Center Support Grant supports the infrastructure of the Holden Comprehensive Cancer Center. This infrastructure allows the Center to foster excellence in research across a broad spectrum of scientific areas relevant to cancer, and translate those advances to the clinic with the goal of reducing the morbidity and mortality of cancer.
|Gorman, Jacob V; Colgan, John D (2018) Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function. Immunology 154:418-433|
|El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68|
|Fama, Angelo; Xiang, Jinhua; Link, Brian K et al. (2018) Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol 182:644-653|
|Xiu, Yan; Dong, Qianze; Li, Qingchang et al. (2018) Stabilization of NF-?B-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia. Cell Rep 22:350-358|
|Armer, Jessica S; Clevenger, Lauren; Davis, Lauren Z et al. (2018) Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer 124:3401-3408|
|Mayo, Zachary; Seyedin, Steven; Marquardt, Michael et al. (2018) Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report. Head Neck :|
|D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426|
|McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182|
|Beck, Anna C; Goffredo, Paolo; Hassan, Imran et al. (2018) Risk factors for 30-day readmission after adrenalectomy. Surgery 164:766-773|
|Gu, Chunyan; Holman, Carol; Sompallae, Ramakrishna et al. (2018) Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer J 8:22|
Showing the most recent 10 out of 1080 publications